Myocarditis and Heart Failure Associated With Hepatitis C Virus Infection

Akira Matsumori, Toshio Shimada, Nora M Chapman, Steven M Tracy, Jay W. Mason

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Background: The aim of study is to determine the prevalence of hepatitis C virus (HCV) infection and myocardial injury among patients enrolled in the Myocarditis Treatment Trial. HCV infection has recently been noted in patients with cardiomyopathies and myocarditis. However, prevalence of HCV infection in myocarditis and heart failure remains to be clarified. Methods and Results: Patients with heart failure up to 2 years in duration without a distinct cause were enrolled in the trial between 1986 and 1990. Frozen blood samples were available from 1355 among 2233 patients enrolled and examined for presence of anti-HCV antibodies, circulating cardiac troponins I and T, and N-terminal pro-brain natriuretic peptide (NT-proBNP). Anti-HCV antibodies were identified in 59 of 1355 patients (4.4%). This higher prevalence of HCV infection than that observed in the general US population (1.8%), varied widely (0-15%) among the different medical centers and regions. The concentrations of circulating cardiac troponin (cTn) I were elevated in 17 of 56 patients (30%), and cTnT was detectable in 28 of 59 patients (48%) with HCV antibodies, suggesting the persistence of ongoing myocardial injury. The concentrations of NT-proBNP were elevated in 42 of 42 patients (100%) with HCV antibodies, (10,000 ± 5860 pg/mL), a mean value significantly greater than in 1276 patients without HCV antibody (2508 ± 160 pg/mL, P < .0001). Conclusion: Anti-HCV antibodies were identifiable in sera stored for 13 to 17 years and were more prevalent in patients with myocarditis and HF than in the general population. In regions where its prevalence is high, HCV infection may be an important cause of myocarditis and HF. NT-proBNP is a more sensitive marker of myocardial injury than cardiac troponins in patients with heart failure from HCV myocarditis.

Original languageEnglish (US)
Pages (from-to)293-298
Number of pages6
JournalJournal of Cardiac Failure
Volume12
Issue number4
DOIs
StatePublished - May 1 2006

Fingerprint

Myocarditis
Virus Diseases
Hepacivirus
Heart Failure
Hepatitis C Antibodies
Brain Natriuretic Peptide
Troponin I
Wounds and Injuries
Troponin T
Troponin
Cardiomyopathies
Population

Keywords

  • Heart failure
  • Hepatitis C virus
  • Myocarditis
  • Troponin
  • proBNP

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Matsumori, A., Shimada, T., Chapman, N. M., Tracy, S. M., & Mason, J. W. (2006). Myocarditis and Heart Failure Associated With Hepatitis C Virus Infection. Journal of Cardiac Failure, 12(4), 293-298. https://doi.org/10.1016/j.cardfail.2005.11.004

Myocarditis and Heart Failure Associated With Hepatitis C Virus Infection. / Matsumori, Akira; Shimada, Toshio; Chapman, Nora M; Tracy, Steven M; Mason, Jay W.

In: Journal of Cardiac Failure, Vol. 12, No. 4, 01.05.2006, p. 293-298.

Research output: Contribution to journalArticle

Matsumori, A, Shimada, T, Chapman, NM, Tracy, SM & Mason, JW 2006, 'Myocarditis and Heart Failure Associated With Hepatitis C Virus Infection', Journal of Cardiac Failure, vol. 12, no. 4, pp. 293-298. https://doi.org/10.1016/j.cardfail.2005.11.004
Matsumori, Akira ; Shimada, Toshio ; Chapman, Nora M ; Tracy, Steven M ; Mason, Jay W. / Myocarditis and Heart Failure Associated With Hepatitis C Virus Infection. In: Journal of Cardiac Failure. 2006 ; Vol. 12, No. 4. pp. 293-298.
@article{7a9e9dc90e39450db2de526f9e883464,
title = "Myocarditis and Heart Failure Associated With Hepatitis C Virus Infection",
abstract = "Background: The aim of study is to determine the prevalence of hepatitis C virus (HCV) infection and myocardial injury among patients enrolled in the Myocarditis Treatment Trial. HCV infection has recently been noted in patients with cardiomyopathies and myocarditis. However, prevalence of HCV infection in myocarditis and heart failure remains to be clarified. Methods and Results: Patients with heart failure up to 2 years in duration without a distinct cause were enrolled in the trial between 1986 and 1990. Frozen blood samples were available from 1355 among 2233 patients enrolled and examined for presence of anti-HCV antibodies, circulating cardiac troponins I and T, and N-terminal pro-brain natriuretic peptide (NT-proBNP). Anti-HCV antibodies were identified in 59 of 1355 patients (4.4{\%}). This higher prevalence of HCV infection than that observed in the general US population (1.8{\%}), varied widely (0-15{\%}) among the different medical centers and regions. The concentrations of circulating cardiac troponin (cTn) I were elevated in 17 of 56 patients (30{\%}), and cTnT was detectable in 28 of 59 patients (48{\%}) with HCV antibodies, suggesting the persistence of ongoing myocardial injury. The concentrations of NT-proBNP were elevated in 42 of 42 patients (100{\%}) with HCV antibodies, (10,000 ± 5860 pg/mL), a mean value significantly greater than in 1276 patients without HCV antibody (2508 ± 160 pg/mL, P < .0001). Conclusion: Anti-HCV antibodies were identifiable in sera stored for 13 to 17 years and were more prevalent in patients with myocarditis and HF than in the general population. In regions where its prevalence is high, HCV infection may be an important cause of myocarditis and HF. NT-proBNP is a more sensitive marker of myocardial injury than cardiac troponins in patients with heart failure from HCV myocarditis.",
keywords = "Heart failure, Hepatitis C virus, Myocarditis, Troponin, proBNP",
author = "Akira Matsumori and Toshio Shimada and Chapman, {Nora M} and Tracy, {Steven M} and Mason, {Jay W.}",
year = "2006",
month = "5",
day = "1",
doi = "10.1016/j.cardfail.2005.11.004",
language = "English (US)",
volume = "12",
pages = "293--298",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Myocarditis and Heart Failure Associated With Hepatitis C Virus Infection

AU - Matsumori, Akira

AU - Shimada, Toshio

AU - Chapman, Nora M

AU - Tracy, Steven M

AU - Mason, Jay W.

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Background: The aim of study is to determine the prevalence of hepatitis C virus (HCV) infection and myocardial injury among patients enrolled in the Myocarditis Treatment Trial. HCV infection has recently been noted in patients with cardiomyopathies and myocarditis. However, prevalence of HCV infection in myocarditis and heart failure remains to be clarified. Methods and Results: Patients with heart failure up to 2 years in duration without a distinct cause were enrolled in the trial between 1986 and 1990. Frozen blood samples were available from 1355 among 2233 patients enrolled and examined for presence of anti-HCV antibodies, circulating cardiac troponins I and T, and N-terminal pro-brain natriuretic peptide (NT-proBNP). Anti-HCV antibodies were identified in 59 of 1355 patients (4.4%). This higher prevalence of HCV infection than that observed in the general US population (1.8%), varied widely (0-15%) among the different medical centers and regions. The concentrations of circulating cardiac troponin (cTn) I were elevated in 17 of 56 patients (30%), and cTnT was detectable in 28 of 59 patients (48%) with HCV antibodies, suggesting the persistence of ongoing myocardial injury. The concentrations of NT-proBNP were elevated in 42 of 42 patients (100%) with HCV antibodies, (10,000 ± 5860 pg/mL), a mean value significantly greater than in 1276 patients without HCV antibody (2508 ± 160 pg/mL, P < .0001). Conclusion: Anti-HCV antibodies were identifiable in sera stored for 13 to 17 years and were more prevalent in patients with myocarditis and HF than in the general population. In regions where its prevalence is high, HCV infection may be an important cause of myocarditis and HF. NT-proBNP is a more sensitive marker of myocardial injury than cardiac troponins in patients with heart failure from HCV myocarditis.

AB - Background: The aim of study is to determine the prevalence of hepatitis C virus (HCV) infection and myocardial injury among patients enrolled in the Myocarditis Treatment Trial. HCV infection has recently been noted in patients with cardiomyopathies and myocarditis. However, prevalence of HCV infection in myocarditis and heart failure remains to be clarified. Methods and Results: Patients with heart failure up to 2 years in duration without a distinct cause were enrolled in the trial between 1986 and 1990. Frozen blood samples were available from 1355 among 2233 patients enrolled and examined for presence of anti-HCV antibodies, circulating cardiac troponins I and T, and N-terminal pro-brain natriuretic peptide (NT-proBNP). Anti-HCV antibodies were identified in 59 of 1355 patients (4.4%). This higher prevalence of HCV infection than that observed in the general US population (1.8%), varied widely (0-15%) among the different medical centers and regions. The concentrations of circulating cardiac troponin (cTn) I were elevated in 17 of 56 patients (30%), and cTnT was detectable in 28 of 59 patients (48%) with HCV antibodies, suggesting the persistence of ongoing myocardial injury. The concentrations of NT-proBNP were elevated in 42 of 42 patients (100%) with HCV antibodies, (10,000 ± 5860 pg/mL), a mean value significantly greater than in 1276 patients without HCV antibody (2508 ± 160 pg/mL, P < .0001). Conclusion: Anti-HCV antibodies were identifiable in sera stored for 13 to 17 years and were more prevalent in patients with myocarditis and HF than in the general population. In regions where its prevalence is high, HCV infection may be an important cause of myocarditis and HF. NT-proBNP is a more sensitive marker of myocardial injury than cardiac troponins in patients with heart failure from HCV myocarditis.

KW - Heart failure

KW - Hepatitis C virus

KW - Myocarditis

KW - Troponin

KW - proBNP

UR - http://www.scopus.com/inward/record.url?scp=33646184446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646184446&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2005.11.004

DO - 10.1016/j.cardfail.2005.11.004

M3 - Article

VL - 12

SP - 293

EP - 298

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 4

ER -